Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Medic Life Sciences Inc. is active in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions. These actions are assigned to 2 distinct examiners, ensuring different perspectives on each matter. This distribution means that each of the 2 pending office actions is reviewed by a separate individual.
Both pending actions are located within 1 distinct art unit. AULAKH, CHARANJIT is the busiest examiner, currently overseeing 1 pending office action. This workload is shared with the other examiner involved in the company's 2 pending actions. Having 2 distinct examiners within 1 distinct art unit allows for specialized technical review with multiple points of contact for the company.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AULAKH, CHARANJIT | 1 | 80.6% | -14.5% |
| HEITMEIER, KENDALL NICOLE | 1 | 65.9% | +41.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18635402 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | AULAKH, CHARANJIT | 475d overdue |
| 18249209 | DOSING REGIMENS FOR CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | HEITMEIER, KENDALL NICOLE | 23d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18249209 | DOSING REGIMENS FOR CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | HEITMEIER, KENDALL NICOLE | 23d |
| Art Unit | Apps |
|---|---|
| 1621 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18635402 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | AULAKH, CHARANJIT | 1621 | §102§112Other | Non-Final OA | 475d overdue | Pending | Apr 15, 2024 |
| 18249209 | DOSING REGIMENS FOR CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | HEITMEIER, KENDALL NICOLE | 1621 | §103§112Other | Final Rejection | 23d | Pending | Apr 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial